PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 946.70K | 899.90K | 2.03M | 1.24M | 753.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.01M | 961.80K | 2.12M | 1.38M | 848.30K |
| Operating Income | -1.01M | -961.80K | -2.12M | -1.38M | -848.30K |
| Income Before Tax | -5.08M | -4.39M | 746.90K | -7.42M | -8.36M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.08M | -4.39M | 746.90K | -7.42M | -8.36M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.08M | -4.39M | 746.90K | -7.42M | -8.36M |
| EBIT | -1.01M | -961.80K | -2.12M | -1.38M | -848.30K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -10.24 | -8.69 | -3.19 | -23.53 | -23.37 |
| Normalized Basic EPS | 0.69 | 1.69 | -1.09 | -12.36 | -9.47 |
| EPS Diluted | -10.24 | -8.69 | -3.19 | -23.53 | -23.37 |
| Normalized Diluted EPS | 0.69 | 1.69 | -1.09 | -12.36 | -9.47 |
| Average Basic Shares Outstanding | 565.00K | 561.00K | 487.50K | 357.70K | 357.70K |
| Average Diluted Shares Outstanding | 565.00K | 561.00K | 487.50K | 357.70K | 357.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.64% | -1.90% | 13.57% | -0.83% | -- |